Navigation Links
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Date:1/12/2009

under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    richard.smith@pharmasset.com
    Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2008 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and E
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
3. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
4. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
5. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
6. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
7. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
8. Pharmasset Joins Russell 3000 Index
9. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
10. Pharmasset Selected to Join the NASDAQ Biotechnology Index
11. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Baltimore, MD (PRWEB) May 23, 2013 ... time off from work motivate members of the public ... of researchers including Johns Hopkins Carey Business School ... an emphatic yes. Pointing to a large body of ... write in the May 24, 2013, issue of Science ...
(Date:5/23/2013)... 23, 2013 The maker community is ... of inventions. They focus on learning practical skills while ... gravitate toward bringing their ideas to life via crowdfunding. ... works on making projects using biology. Glowing Plant has ... to make them glow with bioluminescence genes, and has ...
(Date:5/23/2013)... 23, 2013 BioTrends Research Group, one ... for specialized biopharmaceutical issues, finds that, unaided, one ... specialists reported that in the past six months, ... treatment) in anticipation of the next generation of ... when only 6 percent reported that they had ...
(Date:5/23/2013)... SOUTH EASTON, Mass. , May 23, 2013 /PRNewswire/ ... "Company") today announced that the Company will host a ... and to provide a business update. The teleconference information ... 2013 Time: 11:00 a.m. Eastern Daylight Time (EDT) ... Canada ); (302) 607-2001 (Int,l) Passcode: VS22823 ...
Breaking Biology Technology:Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2
... 11 /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical ... entered into two definitive license agreements with University Health Network ... Toronto, Ontario , granting Trillium exclusive worldwide rights to commercialize ... transplantation and cancer. , ...
... most important technological innovation during human history. This genetic ... used individuals carrying favorable gene variants for breeding purposes. ... international team led by researchers at Uppsala University has ... of the domestic chicken. The domestic chicken has ...
... ... ... , ... , , , , ...
Cached Biology Technology:Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3Scientific breakthrough in genetic studies of animal domestication 2Toxikon Corporation Hosts Extractables and Leachables Spring Seminar 2Toxikon Corporation Hosts Extractables and Leachables Spring Seminar 3
(Date:5/23/2013)... which estrogen suppresses lipid synthesis in the liver, UC ... treating certain liver diseases. , With this finding, ... long-held views in the field. Study results appear in ... Signaling . , "The dogma in the steroid receptor ... located in the nucleus respond to steroid hormones by ...
(Date:5/23/2013)... prostate cancer patients unnecessarily undergo surgery or harsh ... between slow-growing and aggressive forms of the disease. ... Hopkins Medical Institutes are developing technology that allows ... for relatively mild treatments or take drastic measures. ... Madabhushi, an associate professor of biomedical engineering at ...
(Date:5/23/2013)... are billions of animal and plant specimens from birds, ... stacked, stored and preserved in jars and collection drawers. ... to understanding how the Earth,s biodiversity is changing in ... only the information were easily accessible. , A new ... a team from the University of Colorado Boulder, is ...
Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2Using big data to identify prostate cancers and best treatments 2Using big data to identify prostate cancers and best treatments 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 2CU-Boulder helps tap crowds to digitize museum records of bugs and plants 3CU-Boulder helps tap crowds to digitize museum records of bugs and plants 4
... pinpointed a set of common variations in human DNA ... who carry them. Some of these variations are more ... future studies examining whether lupus is more prevalent among ... study. Also, the findings point to various drug ...
... is available in French . , A ... small differences between individuals at the DNA level can ... proteins. These, in turn, are responsible for the vast ... study, part of the Genome Regulators in Disease (GRID) ...
... Centre for Cancer Research at Cardiff University have made ... save the lives of women who become resistant to ... such as tamoxifen have been a huge success in ... the drugs either fail to work, or after an ...
Cached Biology News:DNA variations signal lupus risk 2DNA variations signal lupus risk 3Tiny genetic differences have huge consequences: McGill researchers 2Further breakthroughs for breast cancer patients 2
...
Bovine Pulmonary Artery Endothelial Cells (BPAEC) (>500,000 cells)...
Black Polypropylene 384 Round Well Plate 70/Box...
Spectrolyse (pL) PAI kit is a two-stage indirect enzymatic assay for the quantitative determination of Plasminogen Activator Inhibitor (PAI-1) activity in plasma. Sample Type: plasma...
Biology Products: